Theriva Biologics Inc. (TOVX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Theriva Biologics Inc. stock (TOVX) is currently trading at $0.22. Theriva Biologics Inc. PE ratio is 0.09. Theriva Biologics Inc. PS ratio (Price-to-Sales) is 22.32. Analyst consensus price target for TOVX is $7.00. WallStSmart rates TOVX as Sell.
- TOVX PE ratio analysis and historical PE chart
- TOVX PS ratio (Price-to-Sales) history and trend
- TOVX intrinsic value — DCF, Graham Number, EPV models
- TOVX stock price prediction 2025 2026 2027 2028 2029 2030
- TOVX fair value vs current price
- TOVX insider transactions and insider buying
- Is TOVX undervalued or overvalued?
- Theriva Biologics Inc. financial analysis — revenue, earnings, cash flow
- TOVX Piotroski F-Score and Altman Z-Score
- TOVX analyst price target and Smart Rating
Theriva Biologics Inc.
📊 No data available
Try selecting a different time range
TOVX Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Theriva Biologics Inc. (TOVX)
TOVX trades at a significant discount to its Graham intrinsic value of $14.01, offering a 99% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Theriva Biologics Inc. (TOVX) · 5 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Theriva Biologics Inc. (TOVX) Key Strengths (1)
Trading below book value, meaning the market prices it less than net assets
Supporting Valuation Data
Theriva Biologics Inc. (TOVX) Areas to Watch (4)
Company is destroying shareholder value
Very expensive at 22.3x annual revenue
Very low institutional interest at 3.68%
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Theriva Biologics Inc. (TOVX) Detailed Analysis Report
Overall Assessment
This company scores 19/100 in our Smart Analysis, earning a F grade. Out of 5 metrics analyzed, 1 register as strengths (avg 10.0/10) while 4 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book. Valuation metrics including Price/Book (0.58) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Price/Sales, Institutional Own.. Some valuation metrics including Price/Sales (22.32) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -167.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -167.00% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Price/Sales are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
TOVX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
TOVX's Price-to-Sales ratio of 22.32x trades 33% below its historical average of 33.09x (77th percentile). The current valuation is 96% below its historical high of 560.83x set in Apr 2010, and 1000% above its historical low of 2.03x in Jul 2018. Over the past 12 months, the PS ratio has expanded from ~12.9x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Theriva Biologics Inc. (TOVX) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Theriva Biologics Inc. operates as a stable business with moderate growth and solid fundamentals.
Key Findings
Free cash flow is -3M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Theriva Biologics Inc..
Bottom Line
Theriva Biologics Inc. offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 11:50:14 AM
About Theriva Biologics Inc.(TOVX)
NYSE MKT
HEALTHCARE
BIOTECHNOLOGY
USA
Theriva Biologics Inc., a clinical-stage company, develops therapies to treat diseases in areas of high unmet need. The company is headquartered in Rockville, Maryland.